Description: Oragenics, Inc., a healthcare company, engages in the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits in the United States and internationally. It develops ProBiora3, an oral care probiotics technology for oral health, teeth whitening, and breath freshening for humans and pets. The company's ProBiora3 products include flavored probiotic tablets, such as EvoraPlus for daily use by adults and EvoraKids for daily use by children after brushing their teeth; EvoraPet for companion pets, including cats and dogs; and EvoraPro, a professional strength version of EvoraPlus. Its product pipeline consists of LPT3-04, a naturally occurring compound for weight loss; SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay; and MU1140-S, an antibiotic product candidate in preclinical testing for healthcare-associated infections. Oragenics, Inc. offers its ProBiora3 products through direct-to-consumer channels, professional offices, and private label partnerships. The company was formerly known as Oragen, Inc. The company was founded in 1996 and is headquartered in Tampa, Florida.
Home Page: www.oragenics.com
OGEN Technical Analysis
4902 Eisenhower Boulevard
Tampa,
FL
33634
United States
Phone:
813 286 7900
Officers
| Name | Title |
|---|---|
| Dr. Frederick W. Telling Ph.D. | Exec. Chairman |
| Ms. Kimberly M. Murphy | Pres, CEO & Director |
| Dr. Martin Handfield M.Sc., Ph.D. | Sr. VP of Discovery Research |
Exchange: NYSE MKT
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7019 |
| Price-to-Sales TTM: | 91.269 |
| IPO Date: | 2004-02-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |